Daptomycin

The continuing rise of resistance rates among bacteria today has led to the need for the development of new antibiotics with the ability to circumvent current resistance mechanisms. Daptomycin (Cubicin, Cubist Pharmaceuticals) is an injectable novel lipopeptide antibiotic shown to have excellent in...

Full description

Saved in:
Bibliographic Details
Published inFormulary (Cleveland, Ohio) Vol. 38; no. 11; p. 634
Main Authors Sun, Heather K, Kuti, Joseph L, Nicolau, David P
Format Journal Article
LanguageEnglish
Published North Olmsted MultiMedia Healthcare Inc 01.11.2003
Subjects
Amino acids
Antibiotics
Bacteria
Clinical trials
Drug dosages
Drug resistance
Drug therapy
Gram-positive bacteria
Pathogens
Penicillin
Pharmacodynamics
Pharmacokinetics
Plasma
Staphylococcus infections
Streptococcus infections
Online AccessGet full text

Cover

More Information
Summary:The continuing rise of resistance rates among bacteria today has led to the need for the development of new antibiotics with the ability to circumvent current resistance mechanisms. Daptomycin (Cubicin, Cubist Pharmaceuticals) is an injectable novel lipopeptide antibiotic shown to have excellent in vitro bactericidal activity against gram-positive organisms, including resistant isolates. First in the new class of lipopeptide antibiotics, daptomycin possesses a unique mechanism of action. Clinical studies in patients with complicated skin and skin structure infections have shown daptomycin to be similar in clinical cure rates compared to standard therapy. Daptomycin was recently approved by FDA for the treatment of complicated skin and skin structure infections caused by susceptible strains of specific gram-positive microorganisms. Daptomycin may offer an alternative in the treatment of gram-positive infections, especially when resistance is suspected. (Formulary 2003;38:634-645.) [PUBLICATION ABSTRACT]
ISSN:1082-801X
1938-1166